Becton, Dickinson and Company (NYSE:BDX) Issues FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $12.95-13.15 for the period, compared to the consensus EPS estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Wall Street Analysts Forecast Growth

Separately, Barclays lifted their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an overweight rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $280.00.

Becton, Dickinson and Company Price Performance

NYSE:BDX traded down $5.67 during trading hours on Friday, hitting $234.68. The company’s stock had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.64 and a current ratio of 1.41. The business’s 50-day moving average is $238.45 and its two-hundred day moving average is $240.53. The company has a market capitalization of $67.80 billion, a PE ratio of 51.69, a PEG ratio of 1.93 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the company posted $2.86 earnings per share. As a group, research analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.